Search

Your search keyword '"Virdone, Saverio"' showing total 180 results

Search Constraints

Start Over You searched for: Author "Virdone, Saverio" Remove constraint Author: "Virdone, Saverio"
180 results on '"Virdone, Saverio"'

Search Results

1. Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registries.

6. Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials

9. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

14. Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry

15. Rhythm versus rate control in patients with newly diagnosed atrial fibrillation – Observations from the GARFIELD-AF registry

16. Country and health expenditure are major predictors of withholding anticoagulation in atrial fibrillation patients at high risk of stroke

17. Clinical Outcomes in Older Patients with Atrial Fibrillation: Insights from the GARFIELD-AF Registry

18. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants

19. Determinants and clinical outcomes of patients who refused anticoagulation: findings from the global GARFIELD-AF registry

20. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

21. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

22. Rhythm versus rate control in patients with newly diagnosed atrial fibrillation – Observations from the GARFIELD-AF registry

23. Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials

24. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation: Results From the GARFIELD-AF Registry

27. Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD‐AF registry.

28. Characteristics of people living in Italy after a cancer diagnosis in 2010 and projections to 2020

29. Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry

30. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF

31. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

32. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.

33. Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF.

35. Two-year outcomes of UK patients newly diagnosed with atrial fibrillation : findings from the prospective observational cohort study GARFIELD-AF

38. Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry

39. Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data

40. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation

41. Head and neck and esophageal cancers after liver transplant: results from a multicenter cohort study. Italy, 1997–2010

42. Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: Observational study using prospectively collected registry data

43. Comparative effectiveness of oral anticoagulants in everyday practice

44. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants

45. Sociodemographic and Reproductive Risk Factors for Breast Cancer: A Case-Control Study in the Setif Province, Northern Algeria

46. Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation – results from the GARFIELD-AF registry.

47. Additional file 1: of International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

48. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF

49. WSO891516 Supplemental Material1 - Supplemental material for Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry

50. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF

Catalog

Books, media, physical & digital resources